^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:RG4733 (Notch inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

    Excerpt:
    ...- Histologically confirmed estrogen receptor-positive (ER+) by IHC...
    Trial ID:
    NCT01149356
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

    Excerpt:
    ...- Estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+)...
    Trial ID:
    NCT01208441
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Breast Cancer
    Title:

    A Phase Ib Dose Escalation Trial of RO4929097 (a ?-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)

    Published date:
    10/28/2021
    Excerpt:
    To determine the safety, tolerability and maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of RO4929097 when administered in combination with exemestane in patients with estrogen receptor positive metastatic breast cancer...Of 14 evaluable patients, one had a partial response, 6 had stable disease and 7 progressive disease....Our data indicate that combinations including endocrine therapy and Notch inhibitors deserve further investigation in endocrine-resistant ERα-positive breast cancer.
    Secondary therapy:
    exemestane
    DOI:
    10.1016/j.clbc.2021.10.013